Elmiron Lawsuit: The Vision-Damage Litigation Is Quietly Winding Down
Elmiron - the only FDA-approved pill for interstitial cystitis - was linked in 2018 to a distinctive retinal injury called pigmentary maculopathy. Nearly 2,000 federal lawsuits followed. There was never a public settlement announcement and never a trial verdict; instead, confidential settlements have shrunk the docket year after year, to 286 cases by August 2026. Here is the verified status.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Lawsuits Allege
Plaintiffs allege long-term use of Elmiron (pentosan polysulfate sodium) causes pigmentary maculopathy - a retinal condition first tied to the drug by Emory Eye Center research in 2018 - and that Janssen knew of the signal for years but did not warn. The FDA-approved label added a retinal-damage warning only in June 2020. The injury can be mistaken for age-related macular degeneration; some vision loss appears to progress even after stopping the drug.
Case Details
In re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation, MDL No. 2973, District of New Jersey (Judge Brian R. Martinotti). 1,988 total actions historically; 286 still pending per the JPML's August 3, 2026 statistics. Defendant: Janssen Pharmaceuticals (Johnson & Johnson).
Status: Confidential Settlements, No Public Fund, Docket Shrinking
Who Qualified - and Can New Claims Still Be Filed
The typical signed case involved: two or more years of documented Elmiron use, an eye-exam diagnosis of pigmentary maculopathy or related retinal injury, and use predating the June 2020 label change. New claims are legally possible but face two hard screens: statutes of limitations (running from when you knew or should have known the link - in most states 2-3 years) and firm intake standards that have tightened as the litigation winds down. If you took Elmiron for years and have unexplained retinal findings, a retina-specialist exam plus a prompt attorney consult is the honest advice - the clock, not the science, is the barrier now.
What Cases Reportedly Pay
Elmiron Litigation Timeline
- 1
2018 — Emory Research Links Elmiron to Maculopathy
Ophthalmologists describe a distinctive retinal injury pattern in long-term users.
- 2
June 2020 — FDA Label Adds Retinal Warning
Two years after the first published signal - the gap at the heart of the failure-to-warn claims.
- 3
December 2020 — MDL 2973 Formed
Federal cases consolidate in New Jersey before Judge Martinotti.
- 4
January 2023 — Bellwether Trial Averted
First trial settles on the eve; confidential resolution becomes the pattern.
- 5
2023-2026 — The Quiet Wind-Down
Docket falls from ~1,500 (2024) to 286 pending (August 3, 2026) with no public settlement terms.
Watch Out For
A litigation with secret numbers invites invented ones:
'Average Elmiron payout' tables
Every settlement is confidential. Sites publishing precise per-tier payout charts are guessing - no court record supports any of those figures.
'Elmiron claim deadline approaching' urgency
There is no claim fund and therefore no claim deadline. The only real deadlines are state statutes of limitations, which are individual.
Vision-loss cold calls
Legitimate firms evaluate your pharmacy and eye records before signing you. Callers asking for money or Social Security numbers up front to 'register your Elmiron claim' are not law firms.
Elmiron Lawsuit - FAQ
Is there an Elmiron settlement?
Yes - but confidential. Janssen has settled most of the 1,988 filed cases individually or in groups since 2023. No amounts were ever published and no public claim fund exists.
Can I still file an Elmiron lawsuit in 2026?
Possibly - the MDL remains open with 286 cases. The barrier is the statute of limitations, which typically runs from when you connected your vision problems to Elmiron. A prompt consult determines whether your claim is timely.
How much do Elmiron cases pay?
Unverifiable - settlements are confidential. Attorney estimates range from tens of thousands to high six figures by injury severity; treat every precise 'average payout' figure online as marketing.
What injury does Elmiron allegedly cause?
Pigmentary maculopathy - a retinal condition affecting central vision, identified in long-term users and often misdiagnosed as macular degeneration. Diagnosis requires a dilated retinal exam with imaging.
Is Elmiron still on the market?
Yes, with the retinal-damage warning added in June 2020 and recommended eye monitoring. It remains the only FDA-approved oral medication for interstitial cystitis.
Was there ever a trial?
No. Every scheduled bellwether resolved before verdict - so the causation science was never tested in front of a jury, and both sides kept their risk.
I filed a case years ago - why haven't I been paid?
Ask your attorney, not the internet: settlement timing is case-specific, and lien resolution (Medicare/Medicaid) commonly adds months after agreement.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.